GPA
DNA icon

Guidance Point Advisors’s Ginkgo Bioworks DNA Stock Holding History

Guidance Point Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-625
Closed -$8.36K – 87
2024
Q2 		$8.36K Hold
625
– – ﹤0.01% 82
2024
Q1 		$29K Hold
625
– – 0.01% 85
2023
Q4 		$42.3K Sell
625
-11
-2% -$674 0.02% 65
2023
Q3 		$46K Buy
636
+136
+27% +$10.9K 0.02% 71
2023
Q2 		$37.2K Buy
500
+125
+33% +$7.4K 0.01% 76
2023
Q1 		$19.9K Buy
+375
New +$23.8K 0.01% 77

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Guidance Point Advisors's DNA Position: Q3 2024 in Review

Guidance Point Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 625 shares — an estimated $8.36K sold.

Guidance Point Advisors first reported a position in DNA in Q1 2023 and held it in 6 quarters. The position peaked at $46K in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Guidance Point Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Guidance Point Advisors sold 625 Ginkgo Bioworks shares in Q3 2024, an estimated $8.36K.
  • Guidance Point Advisors first reported a position in Ginkgo Bioworks in Q1 2023 and held it in 6 quarters.
  • Guidance Point Advisors's Ginkgo Bioworks position peaked at $46K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Guidance Point Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.